We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-0.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$357M
AUM Growth
-$64.5M
Cap. Flow
-$58.5M
Cap. Flow %
-16.36%
Top 10 Hldgs %
65.85%
Holding
90
New
23
Increased
14
Reduced
14
Closed
30

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$9.89M
2
IMMU
Immunomedics Inc
IMMU
+$7.7M
3
KITE
Kite Pharma, Inc.
KITE
+$6.12M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$3.75M
5
ARGX icon
argenx
ARGX
+$3.18M

Top Sells

Rank Stock Value
1
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$9.77M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.62M
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$5.98M
4
MRVL icon
Marvell Technology
MRVL
+$5.34M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.58M

Sector Composition

Rank Sector Weight
1 Healthcare 60.37%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBIT icon
76
PUT
XBiotech
XBIT
$68M
– –
-20,000
Closed -$330K
NSTG
77
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-164,932
Closed -$3.28M
NVTA
78
CALL
DELISTED
Invitae Corporation
NVTA
– –
-50,000
Closed -$553K
NVTA
79
PUT
DELISTED
Invitae Corporation
NVTA
– –
-70,000
Closed -$774K
CNCE
80
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-49,051
Closed -$837K
OXFD
81
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-386,100
Closed -$5.98M
PGNX
82
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-100,000
Closed -$944K
PGNX
83
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-150,000
Closed -$1.42M
MDCO
84
DELISTED
Medicines Co
MDCO
– –
-70,000
Closed -$3.42M
ARRY
85
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-120,500
Closed -$1.08M
AVXS
86
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-56,000
Closed -$4.26M
ABCO
87
DELISTED
Advisory Board Co
ABCO
– –
-21,300
Closed -$997K
WBMD
88
CALL
DELISTED
WebMD Health Corp.
WBMD
– –
-190,000
Closed -$10M
ELOS
89
DELISTED
Syneron Medical Ltd
ELOS
– –
-122,400
Closed -$1.29M
NDRM
90
CALL
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-150,000
Closed -$3.98M
1 2 3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Acuta Capital Partners held 90 positions worth $357M, down 15% from $422M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Acuta Capital Partners withdrew a net $58.5M in Q2 2017, closing 30 positions and reducing 14 holdings. Its most notable exit was Oxford Immunotec Global PLC Ordinary Shares, an estimated $5.98M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 61% a quarter earlier, followed by Technology.

Against the trend, Acuta Capital Partners opened a new position in Kite Pharma, Inc. worth $7.78M.

  • Acuta Capital Partners's largest Q2 2017 buy was Kite Pharma, Inc.: 75,000 shares worth $7.78M.
  • Acuta Capital Partners added most to Ascendis Pharma A/S in Q2 2017, an estimated $9.89M increase.
  • Acuta Capital Partners's biggest Q2 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $9.77M.
  • Acuta Capital Partners fully exited Oxford Immunotec Global PLC Ordinary Shares in Q2 2017, selling an estimated $5.98M.
  • Acuta Capital Partners's ten largest holdings make up 66% of its $357M portfolio in Q2 2017.
  • Acuta Capital Partners opened 23 new positions and closed 30 in Q2 2017.
  • Acuta Capital Partners's portfolio value fell 15% quarter-over-quarter to $357M.

Based on Acuta Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.